Halozyme Therapeutics (HALO) Financials: History & Chart

Halozyme Therapeutics, Inc.(HALO)

Biotechnology · San Diego, CA

$109.72+1.41 (+1.30%)

Delayed quote: Oct 6, 2026, 4:00 PM EDT

About Halozyme Therapeutics, Inc.

Halozyme Therapeutics, Inc. is a biopharmaceutical company headquartered in San Diego, California, with operations spanning the United States, Switzerland, Ireland, Belgium, Japan, and other international markets. At its core is the proprietary ENHANZE drug delivery platform, which utilizes a patented recombinant human hyaluronidase enzyme (rHuPH20). This innovative technology significantly enhances the subcutaneous (under-the-skin) administration of a diverse range of injectable medicines. This includes complex biologics such as monoclonal antibodies, various other therapeutic molecules, smaller drug compounds, and even fluids. The company's leading product, Hylenex recombinant, is an rHuPH20 formulation specifically designed to facilitate subcutaneous fluid delivery for hydration. It also plays a crucial role in improving the dispersion and absorption of other injected drugs during subcutaneous urography, and aids in the resorption of radiopaque agents. Halozyme also offers several key therapeutics leveraging its platform, including Perjeta, RITUXAN HYCELA, and MabThera SC, which are used to treat non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL). RITUXAN SC is another offering for CLL patients, while HYQVIA addresses various immunodeficiency disorders. Their development pipeline boasts numerous investigational drugs, such as Tecentriq for non-small cell lung cancer, OCREVUS for multiple sclerosis, and DARZALEX, which targets amyloidosis, smoldering myeloma, and multiple myeloma. Other pipeline candidates include nivolumab for solid tumors, ARGX-113 (a human neonatal Fc receptor), ARGX-117 for autoimmune diseases, and BMS-986179, an anti-CD-73 antibody. Halozyme maintains extensive collaborations with prominent pharmaceutical companies like F. Hoffmann-La Roche, Pfizer Inc., Janssen Biotech, Inc., AbbVie, Inc., Eli Lilly and Company, Bristol-Myers Squibb Company, Alexion Pharma Holding, ARGENX BVBA, and Horizon Therapeutics plc. They also partner with research institutions such as the National Institute of Allergy and Infectious Diseases, the Centre for the AIDS Programme of Research in South Africa, and ViiV Healthcare Limited, particularly focusing on both small and large molecule targets for the treatment and prevention of HIV. The company was established in 1998.

San Diego, CA

423 employees

www.halozyme.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Helen I. Torley

View full financials

Financials

SEC Filings

Quarterly Income Statement (USD)

Swipe horizontally to review earlier periods. The line-item column stays pinned.

Quarterly Report	TTM	Quarter ended Jun 2026	Quarter ended Mar 2026	Quarter ended Dec 2025	Quarter ended Sep 2025	Quarter ended Jun 2025	Quarter ended Mar 2025	Quarter ended Dec 2024	Quarter ended Sep 2024
Revenue	1.66B	481.00M	376.71M	451.77M	354.26M	325.72M	264.86M	298.01M	290.08M
Cost of Goods Sold	363.07M	79.17M	108.75M	102.15M	73.00M	64.12M	66.17M	42.05M	49.43M
Gross Profit	1.30B	401.83M	267.96M	349.62M	281.26M	261.60M	198.70M	255.95M	240.66M
Gross Profit Margin	78.2%	83.5%	71.1%	77.4%	79.4%	80.3%	75.0%	85.9%	83.0%
Total Operating Expenses	356.18M	114.17M	83.44M	95.22M	63.34M	59.16M	57.16M	80.45M	77.46M
Research & Development	102.37M	27.66M	25.56M	31.90M	17.25M	17.54M	14.80M	20.44M	18.46M
Selling, General & Administrative	224.29M	57.00M	57.88M	63.33M	46.09M	41.61M	42.36M	42.25M	41.24M
Operating Income (EBIT)	944.49M	287.65M	184.52M	254.40M	217.92M	202.44M	141.53M	175.50M	163.20M
Operating Margin	56.8%	59.8%	49.0%	56.3%	61.5%	62.2%	53.4%	58.9%	56.3%
Income Before Tax (EBT)	583.34M	284.90M	180.33M	-100.85M	218.96M	204.94M	143.83M	178.21M	165.15M
Interest Income	6.65M	N/A	1.32M	N/A	5.33M	6.89M	N/A	N/A	N/A
Interest Expense	20.30M	5.59M	5.51M	4.91M	4.30M	4.39M	4.53M	4.54M	4.52M
Other Income/Expense	-361.15M	-2.75M	-4.19M	-355.25M	1.04M	2.50M	2.29M	2.71M	1.95M
Net Income	413.60M	229.91M	150.05M	-141.59M	175.22M	165.16M	118.09M	137.01M	137.01M
Income Tax Expense	169.74M	54.99M	30.28M	40.74M	43.73M	39.78M	25.73M	41.20M	28.14M
Net Profit Margin	24.9%	47.8%	39.8%	-31.3%	49.5%	50.7%	44.6%	46.0%	47.2%
EBITDA	1.05B	317.17M	218.25M	281.08M	238.38M	222.90M	161.98M	195.92M	183.56M
EBITDA Margin	63.4%	65.9%	57.9%	62.2%	67.3%	68.4%	61.2%	65.7%	63.3%
Depreciation & Amortization	110.39M	29.51M	33.73M	26.68M	20.46M	20.46M	20.45M	20.41M	20.36M
EPS Basic	3.52	1.96	1.27	-1.20	1.49	1.36	0.96	1.08	1.08
EPS Diluted	3.35	1.90	1.22	-1.20	1.43	1.33	0.93	1.06	1.05
Weighted Average Basic Shares	117.27M	117.27M	118.14M	117.67M	117.22M	121.34M	123.22M	126.41M	126.85M
Weighted Average Diluted Shares	121.22M	121.22M	122.88M	117.67M	122.33M	124.16M	126.64M	129.42M	130.13M

Annual Income Statement (USD)

Swipe horizontally to review earlier years. The line-item column stays pinned.

Annual Report	12/31/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018
Revenue	1.40B	1.02B	829.25M	660.12M	443.31M	267.59M	195.99M	151.86M
Cost of Goods Sold	305.44M	159.42M	192.36M	139.30M	81.41M	43.37M	45.55M	10.14M
Gross Profit	1.09B	855.91M	636.89M	520.81M	361.90M	224.23M	150.45M	141.73M
Gross Profit Margin	78.1%	84.3%	76.8%	78.9%	81.6%	83.8%	76.8%	93.3%
Total Operating Expenses	274.88M	304.43M	299.32M	253.28M	86.00M	79.97M	218.06M	211.06M
Research & Development	81.49M	79.05M	76.36M	66.61M	35.67M	34.24M	140.80M	150.25M
Selling, General & Administrative	193.39M	154.34M	149.18M	143.53M	50.32M	45.74M	77.25M	60.80M
Operating Income (EBIT)	816.29M	551.48M	337.57M	267.53M	275.90M	144.25M	-67.61M	-69.33M
Operating Margin	58.4%	54.3%	40.7%	40.5%	62.2%	53.9%	-34.5%	-45.7%
Income Before Tax (EBT)	466.88M	557.13M	348.33M	248.92M	248.52M	129.30M	-72.25M	-79.79M
Interest Income	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Interest Expense	18.13M	18.09M	18.76M	16.95M	7.53M	20.38M	11.63M	18.04M
Other Income/Expense	-349.42M	5.66M	10.76M	-18.61M	-27.38M	-14.95M	-4.64M	-10.46M
Net Income	316.89M	444.09M	281.59M	202.13M	402.71M	129.09M	-72.24M	-80.33M
Income Tax Expense	149.99M	113.04M	66.73M	46.79M	-154.19M	217K	-11K	537K
Net Profit Margin	22.7%	43.7%	34.0%	30.6%	90.8%	48.2%	-36.9%	-52.9%
EBITDA	904.34M	632.79M	422.43M	317.17M	278.90M	147.54M	-63.54M	-66.94M
EBITDA Margin	64.8%	62.3%	50.9%	48.0%	62.9%	55.1%	-32.4%	-44.1%
Depreciation & Amortization	88.05M	81.31M	84.86M	49.64M	3.00M	3.28M	4.07M	2.39M
EPS Basic	2.64	3.50	2.13	1.48	2.86	0.95	-0.50	-0.56
EPS Diluted	2.56	3.43	2.10	1.44	2.74	0.91	-0.50	-0.56
Weighted Average Basic Shares	119.84M	126.83M	131.93M	136.84M	140.65M	136.21M	144.33M	143.45M
Weighted Average Diluted Shares	123.90M	129.42M	134.20M	140.61M	146.80M	141.46M	144.33M	143.60M

Values are displayed in USD. Negative numbers shown in red.

Values are displayed in USD. Negative numbers are shown in red.